`Date Filed: July 15, 2014
`
`Filed On Behalf Of:
`
`Novartis AG and LTS Lohmann Therapie-Systeme AG
`
`By:
`
`Raymond R. Mandra
`ExelonPatchIPR@fchs.com
`(212) 218-2100
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`NOVEN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`
`NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners
`
`Inter Partes Review No. 2014-00549
`
`U.S. Patent 6,316,023
`
`EXHIBIT LIST 1
`
`
`
`EXHIBIT LIST 1
`
`Pursuant to 37 C.F.R. §42.63(e), Patent Owners Novartis AG and LTS
`
`Lohmann Therapie-Systeme AG submit the following current exhibit list.
`
`Exhibit
`
`2001
`
`2002
`
`Description
`
`Background and Need for the Legislation, House Report of the 112th
`Congress, 1st Session, Rep. 112-98, Part 1, pp. 40-57 (2011),
`reprinted in 2011 U.S.C.C.A.N. 70-87
`
`Novartis Pharm. Corp. v. Watson Labs. Inc., 1:11-cv-01112-RGA (D.
`Del. June 18, 2014) (Trial Opinion)
`
`Dated: July 15, 2014
`
`Respectfully submitted,
`
`/Raymond R. Mandra/
`Raymond R. Mandra
`Registration No. 34,382
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`
`1
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that a copy of the foregoing EXHIBIT LIST 1 was served on July
`
`15, 2014 by causing it to be sent by email to counsel for Petitioner at the following
`
`email addresses:
`
`Steven J. Lee (slee@kenyon.com)
`
`Cynthia Lambert Hardman (chardman@kenyon.com)
`
`Dated: July 15, 2014
`
`/Raymond R. Mandra /
`Raymond R. Mandra
`Registration No. 34,382
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`FCHS_WS 10400316v1.doc